{"filings":[{"id":2052116,"accession_number":"0000896264-26-000050","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-08-04T20:22:22+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2 net loss $21.4M on $223M sales; cuts FY guidance, records $29M Hiya impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.4M (diluted EPS $(1.16)) vs net income of $9.7M ($0.52) a year ago; adjusted EPS $(0.07) vs $0.74.","Recorded $29.1M non-cash goodwill impairment on Hiya; Hiya net sales fell 17% to $28M, subscribers down 17%.","Core Nutritional net sales $192M (-4% YoY); active customers 384,000 (-8%).","FY2026 guidance slashed: consolidated net sales now $910M (prev $925M-$1.0B), net loss $(11)M (prev $20M-$27M), adj. EPS $0.76 (prev $1.95-$2.29).","Balance sheet: $169M cash, zero debt; no share repurchases in Q2; $34M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555036,"accession_number":"0000896264-26-000036","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-05-20T20:24:08+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders re-elect all eight directors, ratify KPMG, approve advisory comp at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each of eight director nominees received over 13.6M votes for; no nominee had material withheld count.","Ratification of KPMG as auditor: 16,286,742 for, 151,736 against, 29,732 abstain.","Advisory vote on executive compensation: 13,811,489 for, 509,777 against, 13,996 abstain.","Approximately 89% of shares (16,468,210) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.02,"calibrated_materiality_score":0.02,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99561,"accession_number":"0000896264-26-000030","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 2026 EPS down 16% YoY to $0.41; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $250M flat YoY; net earnings $7.5M (-20%); diluted EPS $0.41 vs $0.49.","Adjusted diluted EPS $0.61 vs $0.73; adjusted EBITDA $28.4M (-5%).","Core Nutritional active customers 404,000 (-12%); Hiya active subscribers 186,000 (-17%).","Rise Wellness net sales $14M (+741%) from Costco nationwide launch.","Reiterates FY2026 outlook: consolidated net sales $925M–$1.0B; adjusted EPS $1.95–$2.29."],"consensus_eps_estimate":null,"consensus_eps_actual":0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":250218000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115641,"accession_number":"0000896264-26-000014","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net loss $1.8M; core customers down 15%; FY2026 guidance flat to 8% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $1.8M vs profit $4.5M YoY; adjusted diluted EPS $0.60 (down 6% from $0.64).","FY2025 net sales $925M (+8% YoY); core nutritional net sales down 8%, active customers down 15% to 387k.","Recorded $7M goodwill impairment and $6.5M cost realignment charge in Q4, boosting effective tax rate to 72.4%.","FY2026 guidance: consolidated net sales $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.","Hiya net sales grew 17% in FY2025; Rise Wellness net sales tripled; non-core now 16% of consolidated sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":925257000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115638,"accession_number":"0000896264-26-000012","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K/A","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"USANA sets CEO Guest compensation at $850K base, $1.7M RSU; Brown gets $1.5M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Brown transitions to strategic advisor through Dec 31, 2026; receives $825K salary, eligible for 2025 bonus, benefits.","Post-separation Brown gets $1.5M severance in three $500K annual installments starting Jan 1, 2027, plus 18 months COBRA.","Kevin Guest named CEO with $850K base salary, target bonus of 100% of base, and $1.7M 2026 RSU grant.","Guest eligible for long-term performance award tied to relative TSR vs Russell 2000 and absolute positive TSR; potential payout up to $3.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115640,"accession_number":"0000896264-26-000005","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA prelim FY2025 sales ~$925M (beat guidance); FY2026 guidance $925M-$1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2025 net sales of ~$925M, above prior guidance of ~$920M.","FY2026 net sales guidance of $925M-$1.0B; core USANA nutritional seen at $720-765M (down from ~$777M).","Hiya segment guided $140-155M (up from ~$132M); Rise Wellness $65-80M (up from ~$16M).","FY2026 is a 52-week year (one week less than FY2025), impacting core business comparison.","Rise Wellness margins expected at breakeven in FY2026 due to growth investments; working capital rising at both Hiya and Rise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115639,"accession_number":"0000896264-26-000002","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"USANA CEO Jim Brown steps down; Kevin Guest returns as CEO effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Brown stepped down as CEO and President after 19 years; will remain in advisory role.","Kevin Guest, former CEO (2015-2023) and current Executive Chairman, reassumes CEO role effective Jan 8, 2026.","Guest continues as Chairman; board cites focus on accelerating growth and long-term opportunities.","Guest led USANA through record results and global expansion during his prior CEO tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132071,"accession_number":"0000896264-25-000213","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net loss of $6.5M; lowers FY25 EPS guidance to $0.78 from $1.50-$2.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $214M (+7% YoY) but net loss -$6.5M vs +$10.6M prior year; adj. diluted EPS -$0.15.","Direct selling active customers down 14% to 388,000; Hiya subscribers 193,400 (down 3% sequentially).","FY25 guidance cut sharply: diluted EPS $0.78 (prev $1.50-$2.20); adj. diluted EPS $1.73 (prev $2.35-$3.00).","Effective tax rate jumped to 65% from 45%, causing ~$7.6M income tax expense adjustment in Q3.","Company expects $4.7M restructuring charge in Q4 to align costs with sales; cash $145M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":699057000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132070,"accession_number":"0000896264-25-000210","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA preliminary Q3 net loss $6.5M, sales $214M, tax rate spikes to 471%; full-year EPS guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $214M (up from $200M YoY) but operating earnings fall to $1.2M from $15.6M.","Diluted EPS loss $0.36 ($0.56 profit in Q3 2024); adjusted EPS loss $0.15.","Effective tax rate 471% due to annual rate change from 45% to 65%, adding ~$7.5M in extra tax.","Full-year sales expected at or near lower end of prior range; EPS below previously issued range.","Hiya (DTC) sales softer but still expected to achieve double-digit growth for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":699057000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148644,"accession_number":"0000896264-25-000178","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2: net sales +11% to $236M, net earnings -7%; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $236M (+11% YoY); net earnings $9.7M (-7% YoY); diluted EPS $0.52 (-4% YoY).","Adjusted diluted EPS $0.74 (+36% YoY); adjusted EBITDA $30.5M (+13% YoY).","Direct selling Active Customers fell 11% YoY to 418k; Hiya subscribers 200.4k.","Repurchased 528k shares for $15M; ended quarter debt-free with $151M cash.","Reiterated FY2025 outlook: net sales $920M-$1.0B, adjusted EPS $2.35-$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":485387000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148643,"accession_number":"0000896264-25-000175","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"USANA enters $75M revolving credit facility with Bank of America, $200M accordion option","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $75M revolver replaces prior agreement; includes $200M accordion feature subject to conditions.","Interest on Term SOFR loans at Term SOFR plus 1.75%; commitment fee 0.25%.","Financial covenants: minimum consolidated EBITDA of $80M (step-up to $100M after Q3 2026) and funded debt/EBITDA ≤ 2.0x.","No restrictions on cash dividends or share repurchases under the credit agreement.","Obligations secured by pledge of capital stock of subsidiaries via Amended and Restated Security and Pledge Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167501,"accession_number":"0000896264-25-000144","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","8.01"],"status":"ready","headline":"USANA shareholders approve 2025 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected, including Kevin G. Guest and Xia Ding.","2025 Equity Incentive Plan approved, reserving 2.5M shares of common stock for awards.","KPMG LLP ratified as independent registered public accounting firm for fiscal 2025.","Advisory say-on-pay vote approved with ~95% of votes cast in favor.","Plan replaces expiring 2015 Equity Incentive Award Plan; no further grants under prior plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167500,"accession_number":"0000896264-25-000119","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 net sales up 10% to $250M; EPS down 43% to $0.49; reiterates FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $250M (+10% YoY); net earnings $9.4M (-43%); diluted EPS $0.49 vs $0.86.","Adjusted diluted EPS $0.73 (-15%); adjusted EBITDA $30M (-10%).","Direct selling Active Customers 459,000 (-7%); Hiya Active Monthly Subscribers 224,000.","FY2025 outlook reaffirmed: consolidated net sales $920M-$1.0B, diluted EPS $1.50-$2.20.","Repurchased 399,000 shares for $12M; $49M remaining under authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":249539000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184799,"accession_number":"0000896264-25-000082","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"USANA acquires controlling interest in Hiya Health Products; Hiya posts $80.9M revenue, $14.9M net income in 9M 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["USANA acquired controlling interest in Hiya on Dec 23, 2024; audited financials of Hiya now filed.","Hiya's revenue $80.9M, net income $14.9M for nine months ended Sep 30, 2024.","Hiya's FY2023 revenue $68.4M, net loss $467.8K; shows significant growth.","Hiya had $3.85M cash, $8.15M inventory, and zero line-of-credit borrowings as of Sep 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184800,"accession_number":"0000896264-25-000054","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net sales -3% to $214M; net earnings -73% to $4.5M; FY2025 guidance includes Hiya","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $214M (-3% YoY); net earnings $4.5M (-73%); diluted EPS $0.23 (-74%).","FY2024 net sales $855M (-7% YoY); net earnings $42M (-34%); diluted EPS $2.19.","Active customers 454K (-6% YoY); Americas & Europe net sales +1% YoY, Asia Pacific -6%.","Closed acquisition of 78.8% of Hiya on Dec 23, 2024; contributed ~$2M in Q4 sales.","FY2025 outlook: net sales $920M–$1.0B; diluted EPS $1.50–$2.20; adjusted diluted EPS $2.35–$3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":2.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":854503000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201387,"accession_number":"0000896264-24-000235","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"USANA acquires 78.8% stake in Hiya Health for $205M; Hiya had $103M sales, $22M adjusted EBITDA LTM","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 78.8% controlling stake in Hiya Health for $205M cash; closed Dec 23, 2024.","Hiya's LTM (Sept 30, 2024) net sales $103M, net income $19M, adjusted EBITDA $22M.","Hiya serves 200,000+ customers via DTC subscription; net sales grew 50% in 2024 vs 2023.","Transaction expected to be immediately accretive to USANA's 2025 adjusted EBITDA.","Remaining 21.15% rollover equity subject to put/call based on Hiya's future EBITDA; financed from $200M cash on hand and credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201386,"accession_number":"0001628280-24-043281","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net sales $200M (-6% YoY); cuts FY2024 EPS guidance to $2.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 diluted EPS $0.56 vs $0.59 YoY; net sales down 6% to $200M.","Active customers fell 3% YoY to 452,000; Greater China customers rose 6% but sales -4%.","FY2024 outlook narrowed: net sales ~$850M (from $850-880M), EPS $2.45 (from $2.40-2.55).","Balance sheet: $365M cash, debt-free; no shares repurchased in Q3.","Regional weakness: North Asia -15%, Americas & Europe -7% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":1.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":640890000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217405,"accession_number":"0000896264-24-000180","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2 net sales $213M (-11% YoY), EPS $0.54 (-39%); cuts FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $0.54 vs. $0.89 in Q2 2023; net sales $213M down 11% YoY to $238M.","Active customers fell 4% YoY to 468,000; macro pressures and fewer promotions cited.","FY24 outlook: net sales $850-880M (prev $850-920M), EPS $2.40-2.55 (prev $2.40-3.00).","Operating margin revised to 8.0%-8.8%; effective tax rate raised to 43%-44%.","Cash $332M, no debt; no share repurchases in Q2; $62M authorization remaining."],"consensus_eps_estimate":null,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":440669000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237251,"accession_number":"0000896264-24-000168","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders re-elect eight board members, ratify KPMG, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; vote totals ranged from 15.9M (Gilbert Fuller) to 16.86M (Kevin Guest) shares for.","Ratification of KPMG as auditor approved with 17.46M for, 60,804 against, 634 abstain.","Advisory vote on executive compensation approved with 16.56M for, 414,043 against, 3,249 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237250,"accession_number":"0000896264-24-000138","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 net sales $228M (-8% YoY), EPS $0.86, reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $228M (-8% YoY, -5% constant currency); diluted EPS $0.86 (-9% YoY).","Reiterates FY2024 net sales outlook $850-920M and EPS $2.40-$3.00.","Greater China active customers +15% YoY, net sales +3% (+7% constant currency).","Other key markets declined: North Asia net sales -28% YoY, SE Asia -22%, Americas/Europe -12%.","Repurchased 194k shares for $9M in Q1; $62M remaining under share repurchase authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":227800000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254805,"accession_number":"0001157523-24-000176","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net sales $221M, EPS $0.87; FY2023 sales -8%; FY2024 guidance $850-920M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $221M (-3% YoY, +4% seq); diluted EPS $0.87 (+32% YoY).","FY2023 net sales $921M (-8% YoY); diluted EPS $3.30 (-8% YoY).","FY2024 guidance: net sales $850-920M, diluted EPS $2.40-3.00, down from FY2023.","Greater China active customers +5% YoY, +11% seq; North Asia net sales -10% YoY.","No share repurchases in Q4; $71M remaining authorization; cash $330M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":921010000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272274,"accession_number":"0001157523-23-001529","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net sales $213M, EPS $0.59; narrows FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $213M (-9% YoY); diluted EPS $0.59 (-24% YoY).","Active customers 464,000 (-2% YoY); Asia Pacific region sales $170M (-7% YoY).","Greater China net sales $107M (-3% YoY, +2% constant currency); active customers +8%.","FY 2023 outlook narrowed: net sales $900-$920M, EPS $2.80-$3.05 (prev. $900-$950M, $2.65-$3.30).","Repurchased 180K shares for $12M; ended quarter debt-free with $307M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":2.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":699927000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289116,"accession_number":"0001157523-23-001145","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2 net sales $238M (-10% YoY), EPS $0.89; FY2023 guidance raised at low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $238M, down 10% YoY; diluted EPS $0.89 vs $1.00.","Active customers 487k, down 13% YoY; sequential rise in mainland China customers (+5%).","FY2023 guidance: net sales $900-950M (prev $875-950M), EPS $2.65-3.30 (prev $2.40-3.30).","Greater China net sales $129M, +4% sequential; mainland China local-currency sales +10% QoQ.","Plans to open 25th market, India, in late 2023; first new market since 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":486562000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309867,"accession_number":"0001157523-23-000832","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K/A","filed_at":"2023-05-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"USANA CEO-to-be Jim Brown gets $800K base salary; Kevin Guest base cut to $750K as Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Brown's annual base salary as CEO increases from $627K to $800K effective July 1, 2023.","Kevin Guest's base salary as Executive Chair reduces from $945K to $750K effective July 1, 2023.","Both remain eligible for Executive Bonus Plan (Brown at 100% of base target, Guest at 50%).","Both continue eligibility for equity grants under 2015 Plan, 401K, and medical benefits.","Compensation approved by Compensation Committee on May 10, 2023; disclosed via 8-K/A amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309870,"accession_number":"0001157523-23-000825","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders elect all director nominees, ratify KPMG, approve exec compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approximately 89% of outstanding shares represented at May 10, 2023 annual meeting.","All seven director nominees elected with >94% of votes cast in favor (excl. broker non-votes).","KPMG ratified as independent auditor for fiscal 2023 with 17,184,640 votes for (99.8% of votes cast).","Advisory vote on executive compensation approved with 15,943,230 for vs 672,183 against.","Shareholders recommended a 1-year frequency for future say-on-pay votes (15,823,729 votes for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309869,"accession_number":"0001157523-23-000729","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"USANA Health Sciences to enter India in Q3 2023, first new market in 5 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expansion into India expected near end of Q3 2023; first new market in five years.","India launch increases USANA's global footprint to 25 markets.","FY2023 net sales and diluted EPS guidance (issued April 25) already reflects India's modest contribution.","President Jim Brown cites extensive research and preparation for the launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309868,"accession_number":"0001157523-23-000608","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 net sales $248M, EPS $0.95; raises FY23 guidance low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $248M, +9% sequentially but -9% YoY; diluted EPS $0.95 (+44% sequentially, -17% YoY).","FY2023 guidance raised: net sales $875-$950M (previously $850-$950M), EPS $2.40-$3.30 (prev $2.35-$3.30).","Active customers 491,000, flat sequentially, -11% YoY; Asia Pacific net sales $200M (80% of total).","Q1 included ~$12M China COVID-demand benefit and ~$13M price-increase pull-forward; new market expansion planned.","Ended quarter with $295M cash, debt-free; no share repurchases; $83M remaining under authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":248360000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328568,"accession_number":"0001157523-23-000267","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"USANA announces CEO transition: Jim Brown to succeed Kevin Guest as CEO effective July 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Guest will transition to Executive Chairman; Jim Brown named CEO effective July 1, 2023.","Jim Brown has served as President since 2019, previously COO and Chief Production Officer.","Kevin Guest has been CEO since 2015 and Chairman since 2020; will remain involved as Executive Chairman.","Current compensation for both executives unchanged until July 1; new packages to be set by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328567,"accession_number":"0001157523-23-000197","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net sales $228M (-15% YoY), EPS $0.66 (-36%); FY2023 guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $228M, down 15% YoY; diluted EPS $0.66, down 36% YoY.","FY2022 net sales $999M (-16% YoY), EPS $3.59 (-37%); operating cash flow $104M.","Active customers 490,000, down 13% YoY but up 3% sequentially; key markets stabilized.","FY2023 outlook: net sales $850M-$950M, diluted EPS $2.35-$3.30; wide range on China uncertainty.","Ended with $288M cash, debt-free; $83M share buyback remaining; no Q4 repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":998601000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328566,"accession_number":"0001157523-23-000020","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA reports preliminary FY2022 net sales ~$995M, EPS ~$3.65; guides FY2023 net sales $850-950M, EPS $2.35-$3.30","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.","Active Customers ~490,000 at year-end; incremental sales in China from COVID policy shift, but uncertainty persists.","Initial FY2023 guidance: net sales $850-950M, diluted EPS $2.35-$3.30, reflecting lower starting customer base and currency headwinds.","Company to report final Q4/FY2022 results on Feb 7, 2023; conference call Feb 8."],"consensus_eps_estimate":null,"consensus_eps_actual":3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":998601000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346242,"accession_number":"0001157523-22-001382","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 sales $233M (-15% YoY), EPS $0.78; slashes FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $233M, down 15% YoY ($274M); diluted EPS $0.78 vs $1.36, down 43%.","Active customers fell 18% to 474,000; Asia Pacific region sales down 17% constant currency.","FY2022 outlook cut: net sales $955-975M (prev. $1,015-1,065M); EPS $3.15-3.40 (prev. $3.85-4.45).","Operating cash flow $29M; cash $247M, debt-free; no share repurchases in quarter.","Management cites COVID disruptions in Asia, stronger USD headwind of ~$15M (6% of sales)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":770641000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362630,"accession_number":"0001157523-22-000927","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"USANA reappoints J. Scott Nixon as independent director effective July 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands to eight members; seven are independent.","Nixon, retired PwC partner and CPA, earlier served as USANA director 2017–2019.","Appointed to Audit, Compensation, Governance Risk & Nominating, and Sustainability Committees.","No arrangement or family relationship with other directors or officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362629,"accession_number":"0001157523-22-000903","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q2 net sales $264M (-21% YoY), EPS $1.00 (-47%); FY2022 outlook reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $264M (-21% YoY, -18% constant currency); diluted EPS $1.00 vs $1.87 prior year.","Active customers 559K (-14% YoY); Greater China active customers 278K (-8% YoY, +9% sequentially).","FY2022 guidance maintained: net sales $1.015B-$1.065B, diluted EPS $3.85-$4.45.","No share repurchases during quarter; cash $230M; $83M remaining under buyback authorization.","COVID disruptions in mainland China and other key markets drove underperformance; inflationary pressures noted."],"consensus_eps_estimate":null,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":537341000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362628,"accession_number":"0001157523-22-000820","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.","FY2022 guidance cut: net sales now $1.015-1.065B (prev. $1.1-1.2B); EPS $3.85-4.45 (prev. $5.00-5.70).","COVID lockdowns in China and regional sales program disruption drove weaker Q2 results.","CEO Kevin Guest cites lower program participation and inflationary pressures; final Q2 results due July 26."],"consensus_eps_estimate":null,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":537341000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382214,"accession_number":"0001157523-22-000619","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"USANA shareholders re-elect all seven directors, ratify KPMG, and approve say-on-pay at 2022 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approximately 17.37M shares (91% of outstanding) represented at the May 9, 2022 Annual Meeting.","All seven director nominees elected with ~16.1-16.4M votes for; broker non-votes ~915K on each.","Ratification of KPMG as auditor for FY2022: 17,335,468 votes for, 31,969 against, 4,396 abstain.","Advisory say-on-pay approved with 15,716,955 votes for (95.6% of votes cast, excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382213,"accession_number":"0001157523-22-000474","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q1 net sales $273M (-11% YoY), EPS $1.15 (-21% YoY); cuts FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $272.9M, down 11% YoY; diluted EPS $1.15, down 21% from $1.45.","Asia Pacific net sales $218.4M (-13% YoY); Greater China down 10%; Southeast Asia Pacific down 24%.","Active customers 552,000, down 11% YoY; Americas & Europe active customers down 10%.","Revised FY2022 outlook: net sales $1.1-1.2B (was $1.125-1.225B), EPS $5.00-5.70 (was $5.25-6.00).","Company repurchased $25M in shares in Q1; $83M remaining under authorization; cites China COVID lockdowns as headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":272867000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400150,"accession_number":"0001157523-22-000158","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).","FY2021 net sales $1.186B (+5% YoY); diluted EPS $5.73 (-2% YoY); FX benefit $53.6M.","FY2022 guidance: net sales $1.125-$1.225B; diluted EPS $5.25-$6.00; expects net sales acceleration.","Q4 regional: Asia Pacific -15%, Americas/Europe -11%; COVID disruptions hurt key markets; Southeast Asia Pacific -26%.","Ended Q4 with $240M cash, no debt; repurchased 296K shares for $28.9M; $108M buyback remaining."],"consensus_eps_estimate":null,"consensus_eps_actual":5.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":1186464000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419112,"accession_number":"0001157523-21-001255","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2021-10-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA Q3 net sales $274.4M, EPS $1.36; reiterates FY2021 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $274.4M (-8% YoY); diluted EPS $1.36 (-6% YoY).","Active customers 576,000 (-11% YoY); Greater China active customers -13% YoY.","Reiterates FY2021 net sales $1.18-$1.20B, EPS $5.80-$6.00; expects ~$130M free cash flow.","Cash $249M, no debt; repurchased 523k shares for $50M, $137M remaining under authorization.","Supply chain disruptions and inflationary pressures continue; product launches delayed to 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":4.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":919165000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419111,"accession_number":"0001157523-21-001196","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"USANA appoints Xia Ding to board of directors, effective Oct 11, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Xia Ding appointed as independent director; initial term through 2022 annual meeting.","Ms. Ding is Vice President of e-commerce Asia Pacific & Latin America at Nike.","Board expands to eight members, six of whom are independent.","Ms. Ding has not been assigned to any board committees at this time.","She brings e-commerce and digital leadership from Nike, JD.com, and Hanesbrands."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436675,"accession_number":"0001157523-21-001149","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.","FY2021 guidance lowered: net sales $1.18-$1.20B (prev $1.24-$1.28B); EPS $5.80-$6.00 (prev $6.15-$6.50).","CEO cites COVID disruptions, lockdowns, postponed events, and delayed product launches as headwinds.","Board increases share repurchase authorization to $150M (includes $14M remaining)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436674,"accession_number":"0001157523-21-000957","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"USANA adopts nonqualified deferred compensation plan for key employees and named executive officers","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Compensation Committee approved Deferred Compensation Plan on July 26, 2021 for key employees including named executive officers.","Participants may defer compensation; Company may make matching contributions (3-year graded vesting) or non-elective contributions (immediate vesting).","Distributions occur upon separation from service, death, or disability; bookkeeping entries credited/debited based on hypothetical investment elections.","Plan is unfunded and unsecured; Company retains discretion to terminate or amend the plan at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436673,"accession_number":"0001157523-21-000928","cik":896264,"company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"USANA posts record Q2 sales of $336.8M (+30.1% YoY); EPS $1.87 (+41.7% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $336.8M, +30.1% YoY; diluted EPS $1.87, +41.7% YoY; active customers 652K (+8.8%).","Asia Pacific sales $279M (+33.3% YoY); Americas & Europe $57.9M (+16.5% YoY).","Gross margin improved 150bps to 83.1%; associate incentives rose 290bps to 45.7% of sales.","Repurchased 304K shares for $29.7M in Q2; $51M remaining under authorization.","FY2021 outlook reiterated: net sales $1.24-$1.28B, diluted EPS $6.15-$6.50."],"consensus_eps_estimate":null,"consensus_eps_actual":3.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":644813000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":322550000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}